Sementis’ current products are all based upon its proprietary SCV Vector System invented and developed by Dr Paul Howley.
The Sementis Copenhagen Vector (SCV) is a genetically modified virus designed to encourage the body’s own immune system to fight disease. This proprietary technology has been designed to not only be safe but to also be extremely effective through superior immune stimulation.
It is a platform system from which a range of immunotherapeutics have been developed ranging from allergies, cancer and infectious diseases.
The Company’s product development strategy initially focuses on the development of a therapeutic peanut hypo-allergy vaccine for the treatment for peanut allergy and a Chikungunya preventative (prophylactic) vaccine. The technology has broad applications which can potentially lead to partnerships involving license fees based on achieving milestones and royalties.